MedTrace Logo

BK329 and Body Fat Reduction

NCT06628791 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-06

No results posted yet for this study

Summary

This clinical trial aims to determine whether BK329 reduces body fat in adults with overweight or obesity and to assess its safety.

The main questions are:

* Does BK329 reduce body fat in participants?
* What side effects occur when participants take BK329?

Conditions

  • Obesity and Overweight

Interventions

DIETARY_SUPPLEMENT

BK329

Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo 400 mg/day for 12 weeks

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Sang Yeoup Lee, MD, PhD · Pusan National University Yangsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-26
Primary Completion
2024-07-08
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06628791 on ClinicalTrials.gov